Alps Advisors Inc
- SEC CIK
- 0001376113
- Latest filing
- Jul 29, 2026
HALO holding history
Halozyme Therapeutics, Inc. in every 13F filed by Alps Advisors Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
HALO overviewAll 13F holders of HALOFull Q2 2026 holdings
- Shares (Q2 2026)
- 7,868
- Value
- $615.8K
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 7,868 | $615.8K | <0.1% | +86+1.1% | Added | Holders |
| Q1 2026 | 7,782 | $503.0K | <0.1% | +1,790+29.9% | Added | Holders |
| Q4 2025 | 5,992 | $403.3K | <0.1% | +66+1.1% | Added | Holders |
| Q3 2025 | 5,926 | $434.6K | <0.1% | +170+3.0% | Added | Holders |
| Q2 2025 | 5,756 | $299.4K | <0.1% | +70+1.2% | Added | Holders |
| Q1 2025 | 5,686 | $362.8K | <0.1% | −10.0% | Reduced | Holders |
| Q4 2024 | 5,687 | $271.9K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 5,687 | $325.5K | <0.1% | −2,701−32.2% | Reduced | Holders |
| Q2 2024 | 8,388 | $439.2K | <0.1% | −45−0.5% | Reduced | Holders |
| Q1 2024 | 8,433 | $343.1K | <0.1% | −81−1.0% | Reduced | Holders |
| Q4 2023 | 8,514 | $314.7K | <0.1% | −486−5.4% | Reduced | Holders |
| Q3 2023 | 9,000 | $343.8K | <0.1% | +9,000 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −7,638−100.0% | Sold out | Holders |
| Q4 2022 | 7,638 | $434.6K | <0.1% | −31−0.4% | Reduced | Holders |
| Q3 2022 | 7,669 | $303.0K | <0.1% | +7,669 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −8,959−100.0% | Sold out | Holders |
| Q4 2021 | 8,959 | $360.0K | <0.1% | +180+2.1% | Added | Holders |
| Q3 2021 | 8,779 | $357.0K | <0.1% | +8,779 | New | Holders |